Our goal is to transform treatment for a broad range of debilitating diseases by controlling a part of the immune system known as the complement cascade. We ushered in the first new class of complement medicine in 15 years, and now have two approved medicines targeting C3, the central protein in the cascade. These include the first and only therapy for geographic atrophy, a leading cause of blindness around the world. With nearly a dozen clinical and pre-clinical programs underway, we believe we have only begun to unlock the potential of targeting C3 across many serious diseases.